Showing results (111-120 of 132) with videos related to
Sort By:
Pageof 14
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 13, 2015
Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell TransplantationSonata Jodele, Tsuyoshi Fukuda, Kana Mizuno, et al.Blood|January 15, 2020
Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumabSonata Jodele, Christopher E Dandoy, Adam Lane, et al.Frontiers in Oncology|August 7, 2023
Diffuse alveolar hemorrhage after hematopoietic cell transplantation- response to treatments and risk factors for mortalityMichelle L Schoettler, Christopher E Dandoy, Anora Harris, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 17, 2013
An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosisRebecca A Marsh, Mi-Ok Kim, Chunyan Liu, et al.Journal of Pediatric Oncology Nursing : Official Journal of the Association of Pediatric Oncology Nurses|January 2, 2016
Increasing Activities of Daily Living Is as Easy as 1-2-3Deanna Best, Erin Osterkamp, Kathleen Demmel, et al.Blood Advances|April 21, 2023
Intestinal permeability in patients undergoing stem cell transplantation correlates with systemic acute phase responses and dysbiosisYunZu Michele Wang, Sheyar Abdullah, Nathan Luebbering, et al.Transplantation and Cellular Therapy|November 17, 2021
Off-the-Shelf Third-Party Virus-Specific T Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplantation RecipientsJeremy D Rubinstein, Sonata Jodele, Daria Heyenbruch, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 25, 2016
A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell TransplantationPooja Khandelwal, Chie Emoto, Tsuyoshi Fukuda, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 19, 2019
The Natural History of BK Polyomavirus and the Host Immune Response After Stem Cell TransplantationBenjamin L Laskin, Michelle R Denburg, Susan L Furth, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 14, 2015
Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab RegimenRebecca A Marsh, Marepalli B Rao, Aharon Gefen, et al.Pageof 14